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Abstract: A mutation in the JAK2 gene is commonly found in patients with MPN, which can sometimes lead to 
secondary AML. In this case study, we are reporting on an interesting case of secondary AML originating from MDS-
RARS-T. The patient had no gross chromosomal changes, and we found that he was JAK2 V617F-mutated. His BM 
showed 53% of myeloid blasts. After the induction of combined therapy of Venetoclax and Azacytidine, a complete 
remission of the disease was achieved. However, instead of the expected decrease in the mutated JAK2 alleles, we 
documented a rise from the initial 55% to 79% of mutated alleles. This can be explained by the fact that treatment for 
AML targets only one subclone. 
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A somatic mutation in the Janus kinase 2 (JAK2) gene 
is commonly found in patients with myeloproliferative 
neoplasms (MPN). These patients have a proliferation 
of one or more of the myeloid cell lineages in bone 
marrow (BM) and immature cells in the peripheral 
blood (PB). The mutation is found in almost 95% of 
polycythemia vera (PV), approximately half (50-60%) 
of essential thrombocythemia (ET) and half (50-60%) 
of primary myelofibrosis (PMF) patients. The JAK2 
V617F mutation is caused by a G-to-T transversion at 
nucleotide 1849 in exon 14 of the JAK2 gene, resulting 
in a valine-to-phenylalanine amino acid substitution at 
codon 617.
1
 Normally, the binding of JAK kinase to 
the associated cytokine receptor results in a 
conformational change in the cytokine receptor and 
phosphorylation, as well as activation of the JAK 
kinase. Phosphorylated tyrosine residues in JAKs act as 
binding sites for the SH2 domains in signaling 
molecules. This leads to the activation of signal 
transducers and activators of transcription (STATs), 
which then dimerize and enter the nucleus to regulate 
gene transcription.
2
 The JAK2 V617F mutation 
constitutively activates the JAK2-STAT signaling 
pathway, which further influences cell proliferation, 
differentiation, migration, and apoptosis.
3
 It is well 
known that MPN can lead to fibrosis or leukemic 
transformation.
4
 In 2005, Levine et al. identified 4 out 
of 222 acute myeloid leukemia (AML) patients with a 




In this paper, we report on an interesting case of 
secondary AML which had originated from a 
myelodysplastic syndrome including refractory anemia 
with ring sideroblasts and thrombocytosis (MDS-
RARS-T). The patient, a 73-year-old male, first visited 
the department of hematology in another hospital in 
2009. After establishing a diagnosis of refractory 
anemia with ring sideroblasts (RARS), the patient was 
treated with Litalir. Ten years later he developed AML. 
MDS-RARS-T was established based on the findings 
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of refractory anemia with ring sideroblasts and 
thrombocytosis with no gross chromosomal changes. In 
2018, his BM showed no signs of blasts, but in 2019 
the percentage of myeloid blasts rose to 53%. Blasts 
contain immature chromatin, one or more prominent 
nucleoli and a scant cytoplasm. Among other findings, 
conserved erythropoiesis and polymorphic 
megakaryocytes were observed. After the induction of 
therapy, a complete remission of the disease in the BM 
was achieved. However, instead of an expected 
decrease in the mutated JAK2 alleles, we documented a 
rise in the percentage of mutation. 
 
 
MATERIAL AND METHODS 
Sample collection 
Over 13 months (from May 2018), 1 bone marrow and 




DNA extraction from peripheral blood and bone 
marrow samples was carried out using the Quick-DNA 
Miniprep Plus Kit (Zymo Research; cat no. D4069), 
according to the manufacturer's protocols. Each DNA 
sample was quantified using a BioSpec-nano UV-VIS 
spectrophotometer (Shimadzu). Optimal samples had a 
DNA concentration of over 20 ng/µl and an A260/280 
value between 1.8 and 2.0. 
 
 
Real-time quantitative PCR (qPCR)  
Two qPCR assays were performed using primer and 
probe sequences designed by Larsen et al. The 
sequences are as follows: common forward primer 5'-
CTT TCT TTG AAG CAG CAA GTA TGA-3', wild 
type-specific reverse primer 5'-GTA GTT TTA CTT 
ACT CTC GTC TCC ACA TAC-3', JAK2 V617F 
mutation-specific reverse primer 5'-GTA GTT TTA 
CTT ACT CTC GTC TCC ACA TAA-3' and common 
genomic probe 5'- (6-FAM) TGA GCA AGC TTT 
CTC ACA AGC ATT TGG TTT (TAMRA)-3'. The 




The final reaction mixtures contained: 12.5µl 2X 
Brilliant II QPCR High Rox Master Mix (Agilent, cat 
no. 600805-51), 1.5µl 15µM common forward primer, 
1.5µl 15µM either WT or MUT reverse primer, 0.5µl 
10µM probe, 25ng DNA and PCR-grade water to a 
total of 25µl. The PCR thermocycling conditions were 
as follows: 50°C for 2 min; 95°C for 10 min; 50 cycles 
at 95°C for 15 sec and 60°C for 1 min. All qPCR 
assays were performed in duplicate on a 7300 Real-
Time PCR System (Applied Biosystems, Thermofisher 
Scientific). JAK2 V617F was quantified using the ΔCt 
method (threshold 0.2) in comparison to a fivefold 
dilution series of homozygous JAK2 V617F mutated 




In May 2018, a 73-year-old male patient came to us in 
the transformation to secondary AML, which had 
originated from MDS-RARS-T, which he had 
controlled earlier in another hospital. Cytogenetics saw 
no gross chromosomal changes, and we found that he 
was JAK2 V617F-mutated. When he first came to us, 
his BM showed no signs of blasts, but in 2019 the 
percentage of myeloid blasts rose to 53%. The nucleus 
of the blasts contained immature chromatin with 2-3 
prominent nucleoli, while the cytoplasm was scant with 
a greyish-blue hue. Conserved erythropoiesis and 
polymorphic megakaryocytes were also observed. A 
combined protocol of Venetoclax and Azacitidine was 
started. After 6 cycles (approximately 4-5 months, 5 
cycles of treatment) the BM cleared of blasts and 
moderate cytopenia in the blood was established. 
Unexpectedly, instead of a decrease in the mutated 
JAK2 alleles, we documented a rise from the initial 
55% to 79% of mutated alleles. The therapy with 
Venetoclax (anti-BCL2 agent + Azacytidine) was 
continued in monthly cycles. His JAK2 V617F clone 
was monitored. It continued to rise to 88% at month 6 
and 85% at month 9 of treatment (Figure 1). The 
patient is now at month 13 (after cycle 12) and in 
hematological remission with moderate leukopenia 
(3.1x10/9/L) and no immature cells in his blood 
differential. Anemia of 80-90 g/L is also present, but 




Figure 1. The percentage of the JAK2 V617F mutation in 
response to therapy. Even though a complete remission was 
achieved with combined therapy of Ventoclax and Azacytidine, the 





Changes in the degrees of apoptosis (programmed cell 
death) are involved in the regulation of blood cell 
numbers.
8, 9, 10, 11, 12
 It has been hypothesized that 
 
 Tupek KM 
DOI: 10.33602/mebm.3.1.8 
Molecular and Experimental Biology in Medicine, 2020, 3(1): 48-51 
 
progression to AML in MDS may be due to a reduction 
in apoptosis in the patients' hematopoietic precursors, 
resulting in their accumulation, as well as the potential 
for additional differentiation abnormalities.
13
 Such a 
mechanism of tumorigenesis has been demonstrated in 
certain neoplasms, e.g. follicular lymphomas. Recent 
reports have shown decreased apoptosis in blasts of 
AML and advanced MDS, providing support for this 
mechanism in leukemogenesis. In their research on in-
situ labeling of DNA strand breaks to detect apoptosis 
in BM biopsy sections, Raza et al. reported low 
labeling in AML blasts and blast clusters of advanced 
MDS.
 14, 15, 16
 Rajapaksa et al. used fluorometry and 
flow cytometry to measure DNA fragmentation as 
evidence of apoptosis in immature CD34-positive 
(CD34
pos
) cells from BM aspirates. They found 
significantly lower values for advanced MDS (RAEB 
and RAEB-T) and AML patients in comparison to 
healthy and early MDS patients (RA and RARS).
17
 
This led to the suggestion of an immature 
hematopoietic cell population with decreased apoptosis 
arising from a background of increased apoptosis in 
early MDS. 





, and gene-manipulated cells of several 
lineages against apoptosis.
21, 22
 Data strongly suggests 
that over-expression of Bcl-2 plays a central role in the 
pathogenesis of most cases of follicular lymphomas. 
The over-expression of Bcl-2 leads to prolonged 
survival, decreased apoptosis and accumulation of 
neoplastic cells, although Bcl-2 is expressed in normal 
lymphoid cells as well.
19, 23, 24
 Similarly, Bcl-2 is over-
expressed in blasts in most cases of AML and, in the 
small number of MDS patients studied, associated with 
a worse prognosis.
25, 26, 27
 Bcl-2 is also expressed by 
normal myeloid precursors, in levels which decrease as 
myeloid cells mature. Increased blast accumulation is 
positively correlated with Bcl-2 expression, which is 
shown by in vitro studies of AML blasts.
26, 27, 28
 Other 
in vitro studies of various CD34pos myeloid cells 
(blasts from normal BM, BCL-2-positive myeloid 
leukemic cell lines, and cells from AML patients) 
report that exposure to Bcl-2 antisense oligonucleotides 
reduces the expression of Bcl-2, which is accompanied 
by decreases in both cell growth and resistance to 
chemotherapeutic agents.
29
 The Bcl-2 oncoprotein also 
prolongs cellular survival in cytokine-deprived 
hematopoietic cells by blocking apoptosis.
21, 30, 31
 With 
regard to the combined therapy of Venetoclax and 
Azacytidine, which targets cells with Bcl-2 expression 
and acts as a demethylating agent
32
, the percentage of 
JAK2 V617F can be explained by an untouched cell 
subclone. Furthermore, checking the degree of 
methylation of the JAK2 gene might give us some 
insight into understanding the increased percentage of 
the JAK2 V617F mutation.  
Although it was presumed that the chronic pre-
leukemic clone would regress with the treatment, as 
was observed with the leukemic clone, the observed 
findings can be explained by the fact that treatment for 
AML resets the clone to an earlier stage, but does not 
eradicate it, or it targets only one subclone. It is not 
always clear what this means clinically, as is described 
for DNMT3A, TET2 and ASXL1 persistence after 
chemotherapy for (de novo) AML and this does not 
necessarily predict relapse.
33
 One of the scenarios for 
the patient is that he will go back to his RARS-T/MDS 
for a period, which may be why his JAK2 V617F is 
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